Showing results (531-540 of 3,716) with videos related to
Sort By:
Pageof 372
Investigational New Drugs|February 4, 2018
The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cellsAlexandra Canonici, Zulfiqar Qadir, Neil T Conlon, et al.Investigational New Drugs|November 5, 2017
Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutationsMotohiro Tamiya, Akihiro Tamiya, Takayuki Shiroyama, et al.Investigational New Drugs|January 18, 2018
Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case reportKenta Ogawa, Jiro Ito, Daichi Fujimoto, et al.Investigational New Drugs|March 18, 2018
The molecular mechanism of anticancer action of novel octahydropyrazino[2,1-a:5,4-a']diisoquinoline derivatives in human gastric cancer cellsNatalia Pawłowska, Agnieszka Gornowicz, Anna Bielawska, et al.Investigational New Drugs|September 1, 1988
Anticancer activity of bisphosphonic acids in methylnitrosourea-induced mammary carcinoma of the rat--benefit of combining bisphosphonates with cytostatic agentsF Wingen, B L Pool, P Klein, et al.Investigational New Drugs|December 21, 2018
MICONIDINE acetate, a new selective and cytotoxic compound with synergic potential, induces cell cycle arrest and apoptosis in leukemia cellsMariana Franzoni Maioral, Natália Marceli Stefanes, Álisson Bigolin, et al.Investigational New Drugs|December 21, 2018
Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteersLisa Seitz, Lixia Jin, Manmohan Leleti, et al.Investigational New Drugs|March 30, 2018
Acquired resistance to an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in an uncommon G719S EGFR mutationAtsushi Osoegawa, Takafumi Hashimoto, Yohei Takumi, et al.Investigational New Drugs|July 9, 2008
Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cellsBetty K Samulitis, Terry H Landowski, Robert T DorrInvestigational New Drugs|July 10, 2008
N-benzoxazol-2-yl-N'-1-(isoquinolin-3-yl-ethylidene)-hydrazine, a novel compound with antitumor activity, induces radicals and dissipation of mitochondrial membrane potentialJohann Hofmann, Johnny Easmon, Gerhard Puerstinger, et al.Pageof 372